Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2′-deoxycytidine

被引:43
作者
Cecconi, D
Astner, H
Donadelli, M
Palmieri, M
Missiaglia, E
Hamdan, M
Scarpa, A
Righetti, PG
机构
[1] Univ Verona, Dept Agr & Ind Biotechnol, I-37134 Verona, Italy
[2] Univ Verona, Dept Neurol & Visual Sci, Biochem Sect, I-37134 Verona, Italy
[3] Univ Verona, Dept Pathol, Sect Anatom Pathol, I-37134 Verona, Italy
[4] GlaxoSmithKline, Verona, Italy
关键词
ductal carcinomas; pancreatic tumors; proteomics;
D O I
10.1002/elps.200305724
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A pancreatic adenocarcinoma cell line (PaCa44), which contains, among other alterations , a methylated p16 promoter, was treated with a chemoterapeutic agent, 5-aza-2'deoxycytidine (DAC), in order to evaluate the effect of this drug on cell growth and protein expression. Cell proliferation was strongly inhibited by a 24 h DAC treatment and this inhibition lasted for at least 10 days. Master maps of control and treated PaCa44 cells were generated by analysis with the PDQuest software. The comparison between such maps showed up- and downregulation of 45 polypeptide chains, of which 32 were downregulated and 13 upregulated, out of a total of 700 spots detected by a medium-sensitivity stain, micellar Coomassie Brilliant Blue. Fingerprinting by mass spectrometry analysis enabled the identification of 36 of these spots. Among the major changes in DAC-treated cells: cofilin and profilin 1 are silenced; coactosin, peptidyl-propyl cis-trans isomerase A and cystatin B are decreased by 22, 16- and 15-fold, respectively; stress-70 protein, superoxide dismutase and protein disulfide isomerase A3 are increased by 13-, 11 -, and 5-fold, respectively. The significance of some of these major changes is discussed.
引用
收藏
页码:4291 / 4303
页数:13
相关论文
共 51 条
  • [31] Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis
    Moore, PS
    Orlandini, S
    Zamboni, G
    Capelli, P
    Rigaud, G
    Falconi, M
    Bassi, C
    Lemoine, NR
    Scarpa, A
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (02) : 253 - 262
  • [32] Nakatsura T, 2002, EUR J IMMUNOL, V32, P826, DOI 10.1002/1521-4141(200203)32:3<826::AID-IMMU826>3.0.CO
  • [33] 2-Y
  • [34] Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma
    Pencil, SD
    Toth, M
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (02) : 113 - 121
  • [35] 5-Lipoxygenase interacts with coactosin-like protein
    Provost, P
    Doucet, J
    Hammarberg, T
    Gerisch, G
    Samuelsson, B
    Rådmark, O
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) : 16520 - 16527
  • [36] Coactosin-like protein, a human F-actin-binding protein:: critical role lysine-75
    Provost, P
    Doucet, J
    Stock, A
    Gerisch, G
    Samuelsson, B
    Rådmark, O
    [J]. BIOCHEMICAL JOURNAL, 2001, 359 (02) : 255 - 263
  • [37] Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent
    Rhee, NJ
    Kim, GY
    Huh, JW
    Kim, SW
    Na, DS
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (11): : 3220 - 3225
  • [38] Righetti P.G., 2001, PROTEOME REVISITED
  • [39] DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
    Robertson, KD
    Ait-Si-Ali, S
    Yokochi, T
    Wade, PA
    Jones, PL
    Wolffe, AP
    [J]. NATURE GENETICS, 2000, 25 (03) : 338 - 342
  • [40] DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
    Rountree, MR
    Bachman, KE
    Baylin, SB
    [J]. NATURE GENETICS, 2000, 25 (03) : 269 - 277